Antibody-based Theranostics
Antibody-Based Theranostics is a targeted molecular strategy within theranostic oncology that integrates monoclonal antibodies for both diagnostic imaging and therapeutic intervention, leveraging their high specificity toward tumor-associated antigens to enable precise cancer detection, monitoring, and treatment delivery.
60
Publications
2.8K
Citations
537
Authors
209
Institutions
Publications per year
2017–2026
43
Parents
60
Immunogenicity Risk Profile of Nanobodies
Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier et al. · Frontiers in Immunology · 2021 · 218 citations · Full text
Pharmacy, Immunology, Oncology +17
Antibody-displaying extracellular vesicles for targeted cancer therapy
Oscar P. B. Wiklander, Doste R. Mamand, Wenyi Zheng et al. · Nature Biomedical Engineering · 2024 · 124 citations · Full text
Pharmacy, Oncology, Pharmaceutics +17
1–5 of 60
537
5
h-index
5
h-index
4
h-index
4
h-index
4
h-index
1–5 of 537
209
University of Wisconsin–Madison
Madison, United States
5 h-index
33 publications
1.4K citations
Vrije Universiteit Brussel
Brussels, Belgium
4 h-index
27 publications
3.4K citations

Peking University
Beijing, China
4 h-index
16 publications
729 citations

Shanghai Jiao Tong University
Shanghai, China
4 h-index
12 publications
874 citations

Huazhong University of Science and Technology
Wuhan, China
3 h-index
16 publications
1K citations

Cornell University
Ithaca, United States
3 h-index
6 publications
425 citations

Centre National de la Recherche Scientifique
Paris, France
3 h-index
3 publications
75 citations
Memorial Sloan Kettering Cancer Center
New York, United States
3 h-index
20 publications
1.1K citations
1–8 of 209
7 publications · 243 citations
7
h-index
5 publications · 183 citations
5
h-index
4 publications · 293 citations
4
h-index
NMB · 3 publications · 95 citations
3
h-index
2 publications · 111 citations
2
h-index
1–5